| Symbol | ABCL |
|---|---|
| Name | ABCELLERA BIOLOGICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceuticals and Biotechnology |
| Address | 2215 YUKON STREET, VANCOUVER, British Columbia, V5Y 0A1, Canada |
| Telephone | +1 604 559-9005 |
| Fax | — |
| — | |
| Website | https://www.abcellera.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001703057 |
| Description | AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The companys AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. Additional info from NASDAQ: |
Press Release: AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Read moreAbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Read moreDirector Seely Lynn 🟢 acquired 152.2K shares (1 derivative) of AbCellera Biologics Inc. (ABCL) at $7.85 ($1.2M) Transaction Date: Jul 01, 2026 | Filing ID: 047400
Read moreDirector Sandor Victor 🟢 acquired 152.2K shares (1 derivative) of AbCellera Biologics Inc. (ABCL) at $7.85 ($1.2M) Transaction Date: Jul 01, 2026 | Filing ID: 047396
Read moreNew Form 3 - AbCellera Biologics Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001628280-26-047399 <b>Size:</b> 3 KB
Read morePress Release: AbCellera Appoints Dr. Lynn Seely to its Board of Directors
Read morePress Release: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07108894 | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Part… | Phase1 | Healthy Volunteers | Active_Not_Recruiting | 2025-07-25 | 2027-04-01 | ClinicalTrials.gov |
| NCT07118891 | Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | Phase1 | Vasomotor Symptoms Associated With Menopause | Active_Not_Recruiting | 2025-06-23 | 2027-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo (Normal Saline 0.9%) | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07108894 |
| ABCL575 | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT07108894 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | ACTIVE_NOT_RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | ACTIVE_NOT_RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo (Normal Saline 0.9%) | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07108894 |
| ABCL575 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07108894 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | Other | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo | BIOLOGICAL | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | BIOLOGICAL | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo (Normal Saline 0.9%) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07108894 |
| ABCL575 | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07108894 |